| Size | Price | Stock | Qty |
|---|---|---|---|
| 5KU |
|
||
| 10KU |
|
||
| 25KU |
|
||
| 50KU |
|
| Targets |
Serratia marcescens nuclease is a non-specific endonuclease that targets both DNA and RNA substrates. As an enzyme, its primary targets are nucleic acids, which it cleaves by hydrolyzing phosphodiester bonds. The enzyme exhibits potent digestive activity toward both DNA and RNA substrates, including single-stranded, double-stranded, linear, and circular forms. It produces 5' monophosphate-terminated oligonucleotides of 3-5 bases in length. Its mechanism of action involves cleavage of phosphodiester bonds in nucleic acids, regardless of sequence.
|
|---|---|
| ln Vitro |
In vitro, Serratia marcescens nuclease is used as a biochemical reagent for nucleic acid degradation and removal in molecular biology applications. It is used to remove nucleic acids from protein samples, to reduce viscosity in cell lysates, and to eliminate nucleic acid contamination in biopharmaceutical production. The enzyme's high specific activity and broad substrate specificity make it valuable for various applications, including protein purification, sample preparation for electrophoresis, and removal of DNA/RNA from recombinant protein preparations. Cellular assays may evaluate its effectiveness in degrading nucleic acids in cell lysates.
|
| ln Vivo |
In vivo, Serratia marcescens nuclease is not used as a therapeutic agent but has applications in biopharmaceutical manufacturing to remove nucleic acid contaminants from recombinant protein products. The enzyme is classified for research use and as a manufacturing aid, not for human or veterinary therapeutic applications. Its primary value lies in its use as a research reagent and in biopharmaceutical production to ensure product purity. Specific in vivo data for therapeutic applications is not available.
|
| Enzyme Assay |
In vitro enzyme assays for Serratia marcescens nuclease typically evaluate its nuclease activity. A standard protocol involves incubating the enzyme with nucleic acid substrates (e.g., DNA or RNA) in appropriate buffer systems (e.g., Tris-HCl, pH 8.0, with Mg²⁺). The enzyme is diluted to working concentrations (typically 0.1-10 U/μL). Nuclease activity is measured by monitoring the decrease in absorbance at 260 nm (hyperchromic effect) due to nucleic acid degradation, or by gel electrophoresis to visualize DNA/RNA fragmentation. One unit of activity is defined as the amount of enzyme that causes a ΔA₂₆₀ of 1.0 per minute under standard conditions.
|
| Cell Assay |
Cellular assays for Serratia marcescens nuclease typically evaluate its ability to degrade nucleic acids in cell lysates. A standard protocol involves lysing cells in a buffer containing the nuclease and incubating at 37°C for a defined period. Nucleic acid degradation is assessed by agarose gel electrophoresis or by measuring DNA/RNA concentration using fluorometric assays (e.g., PicoGreen, RiboGreen). The enzyme's effectiveness in reducing viscosity or removing nucleic acid contaminants is evaluated. Protein integrity is assessed by SDS-PAGE to ensure the nuclease does not degrade proteins of interest.
|
| Animal Protocol |
In vivo animal studies for Serratia marcescens nuclease are not standard, as it is primarily an in vitro research reagent and manufacturing aid. The enzyme is classified for research use only and is not intended for human or veterinary therapeutic applications. Any animal studies would be limited to evaluating the enzyme's safety as a manufacturing aid in biopharmaceutical production. The enzyme's primary value lies in its use as a research reagent and in biopharmaceutical manufacturing. Specific in vivo protocols are not available in the public literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Serratia marcescens nuclease is not applicable, as it is an enzyme used as a research reagent and manufacturing aid rather than a therapeutic agent. The enzyme has a molecular weight of approximately 28-30 kDa (monomer) and forms a dimer of ~60 kDa. It is a colorless clear liquid with an activity of ≥1.5×10⁶ U/mg. The enzyme is stored in buffered aqueous glycerol solution at -20°C. As a protein, it would be degraded by proteases if administered systemically. Specific ADME data is not available.
|
| Toxicity/Toxicokinetics |
Serratia marcescens nuclease is classified for research use only and is not intended for human or veterinary therapeutic applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The enzyme should be stored at -20°C in appropriate buffer to maintain activity. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values or detailed toxicological profiles are available in the public domain.
|
| References |
[1]. "Vafina G, et al. Endonuclease from Gram-Negative Bacteria Serratia marcescens Is as Effective as Pulmozyme in the Hydrolysis of DNA in Sputum. Front Pharmacol. 2018;9:114. Published 2018 Feb 16. doi: "
[2]. "Friedhoff P, et al. A procedure for renaturation and purification of the extracellular Serratia marcescens nuclease from genetically engineered Escherichia coli. Protein Expr Purif. 1994;5(1):37-43. " |
| Additional Infomation |
Serratia marcescens nuclease (EC 3.1.30.2, Benzonase, CAS 9025-65-4) is a non-specific endonuclease derived from Serratia marcescens. It exhibits high specific activity and can completely digest all forms of DNA and RNA, producing 5' monophosphate-terminated oligonucleotides. The enzyme is widely used in molecular biology for nucleic acid removal and in biopharmaceutical manufacturing to eliminate nucleic acid contaminants. It is classified as a research-use-only reagent and is available from multiple commercial suppliers. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent.
|
| CAS # |
9025-65-4
|
|---|---|
| Appearance |
Liquid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
413.1±45.0 °C at 760 mmHg
|
| Flash Point |
203.6±28.7 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.605
|
| LogP |
1.19
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
